Clinical Trials

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01475110 2022-10-25

CML0609

Completed

19 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02602314 2022-01-20

SUSTRENIM

Phase 4 Unknown

450 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00769327 2022-01-04

CML0408

129 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00210119 2021-11-08

AFR22

19 enrolled 4 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04883125 2021-05-12

Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00301093 2020-10-28

Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Phase 1 Completed

3 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00219739 2020-04-13

SPIRIT

789 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

LymphoidMyeloidOther hematologic neoplasm

28 enrolled 10 charts

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01578213 2019-12-03

ISAV

Phase 4 Completed

112 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02174445 2019-12-02

DECLINE

Phase 3 Terminated

14 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00632255 2019-07-08

Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

Completed

88 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00047502 2018-11-07

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Phase 1 Completed

23 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02709083 2018-11-02

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

7 enrolled 5 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00038649 2018-10-09

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

117 enrolled 6 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00415857 2018-08-21

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

5 enrolled 3 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00055874 2018-05-03

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

1,551 enrolled

Phase EARLY_PHASE1 Unknown

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03228303 2017-10-10

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00852566 2017-09-25

NordCML006

46 enrolled

LymphoidMyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00702403 2017-08-10

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Phase 1/2 Completed

40 enrolled 12 charts

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03241199 2017-08-08

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

Phase 2 Unknown

15 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00136409 2016-12-23

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

34 enrolled

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT00845221 2016-10-11

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Phase 4 Completed

44 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02146846 2016-09-07

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Terminated

170 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Phase 4 Completed

10 enrolled

Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

NCT00050531 2016-05-11

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

94 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01092741 2016-05-11

Late Chronic Phase Chronic Myelogenous Leukemia

47 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02687425 2016-02-22

SESPI

Phase 2 Unknown

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00022490 2016-01-07

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

24 enrolled 6 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02480608 2015-06-24

CML2004

Phase 1/2 Completed

113 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01188889 2015-05-15

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Phase 1/2 Withdrawn

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00430066 2014-10-08

Effects of Imatinib Mesylate in Polycythemia Vera

9 enrolled

Myeloid

Polycythemia Vera

NCT00415909 2014-06-30

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

3 enrolled 6 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01400074 2014-01-13

RE-NICE

Phase 3 Unknown

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01819389 2014-01-07

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

10 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00045422 2013-06-05

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00066326 2013-04-05

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

Phase 1 Completed

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT01221376 2013-03-26

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Phase 2 Unknown

20 enrolled